Skip to content
FrontierPicks

Filtered library · Theme

M&A & special situations theme · 96 dossiers

Dossiers in the M&A & special situations theme cluster — 96 names moving on shared catalysts.

All dossiers
IRDM Iridium Communications Inc fresh MEDIUM Deal-arb: $27.00 cash plus a collared RKLB stock leg marks a $54.00 package against the 2026-08-24 close of $47.30, a 12.41% discount. The S-4/A filed 2026-08-24 finally dated the special meeting (2026-09-24), but RKLB at $68.28 sits just… Earnings inflection · M&A & special situations · Space economy catalyst · XPO XPO, Inc. fresh LOW Record 79.9% adjusted LTL operating ratio and a raised full-year guide (2026-07-30) now sit against two negative July industry prints — ATA tonnage -0.5% YoY and Cass shipments -4.8% YoY. The $197.01 shelf gave way on the 2026-08-24 close… Compounder · Freight & logistics · Cyclical industrials catalyst · MRX Marex Group plc HIGH Roll-up compounder in clean momentum continuation: the sell-side is now chasing price, with KBW $80, Barclays $76 and Piper $75 targets (Jul 9-15) leapfrogging the old $60 consensus, while the Bright Point clearing bolt-on (2026-07-09)… Cyclical recovery · M&A & special situations · Crypto exchanges & financials catalyst · ACIW ACI Worldwide, Inc. MEDIUM Special-situation breakup narrative accelerating: Reuters (2026-07-17) reports ACI exploring a ~$1.5B sale of its Biller unit, which would surface sum-of-the-parts value and re-rate the faster-growing Payments Software segment. Q1 beat +… Special situation · M&A & special situations · Fintech & consumer credit catalyst · ACLS Axcelis Technologies, Inc. MEDIUM Beat-and-raise on 2026-08-06 (Q2 rev $215.175M vs $204.985M est; Q3 guided $230.0M vs $214.846M) repaired the fundamental case, but price only recovered to the top of the July band at $140.15 (08-14), 26.9% under the $191.6 high. China… Earnings inflection · Semi foundry & equipment · AI chips & memory analysed · BH Biglari Holdings Inc. MEDIUM Q2 10-Q (filed 2026-08-07) answered the dilution question early: six-month issuance proceeds of $14,920k do not exceed the $15,073k of ATM sales already disclosed through 2026-05-08, so nothing material was sold into the June run to… Special situation · Consumer discretionary rotation · M&A & special situations analysed · BMY Bristol-Myers Squibb Co. MEDIUM Legacy-pharma re-rate off the 2026-07-30 guidance reset ($49.0–50.0B sales, $6.75–7.00 adj EPS) is intact, but both attention legs are spent: the AstraZeneca merger was denied 2026-08-05 and the FDA approved ZENBEXUS on 2026-08-13, four… Special situation · Precision biotech & therapeutics · Oncology & immunology catalyst · CCC CCC Intelligent Solutions Holdings Inc. MEDIUM Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is… Earnings inflection · M&A & special situations · AI enterprise software analysed · CODI Compass Diversified MEDIUM Q2 (2026-08-10) reframed the name: adj EPS $(0.09) missed $0.09 est, but Subsidiary Adj EBITDA rose 12.6% to $91.5M and covenant leverage fell 5.3x to 4.8x. TD Cowen went $12.50→$18. Riley upgraded to Buy at $15 on 2026-08-11; three… Special situation · M&A & special situations · Consumer discretionary rotation analysed · DINO HF Sinclair Corporation MEDIUM Post-print leg extended rather than renewed: a fresh 52-week high at $97.32 (2026-08-21), +40.1% over three months, built on the 2026-07-28 beat ($5.31 vs $4.54), the Lubricants spin-off plan and the 2026-08-11 $5B Western Gateway FID.… Compounder · Oil, energy & geopolitical · M&A & special situations analysed · FA First Advantage Corporation MEDIUM Aug 6 flipped the frame: Q2 revenue $448.8M/+14.9% vs $415.0M consensus, adj EPS $0.35 vs $0.28, and the first FY guide raise of the cycle ($1.67–1.71B). Needham upgraded to Buy/$28, RBC to $24 — targets moved above spot for the first… Special situation · Prediction markets & betting · M&A & special situations catalyst · HPP Hudson Pacific Properties, Inc. MEDIUM The refi binary now has a filed date: the 10-Q (2026-08-10) puts the Hollywood Media Portfolio loan maturity at 2026-09-09 with the longer-term extension still unresolved. Q2 beat ($0.35 Core FFO vs $0.26) and three August target raises… Earnings inflection · Freight & logistics · M&A & special situations catalyst · IDYA IDEAYA Biosciences, Inc. MEDIUM Approval leg intact but between catalysts: the OptimUM-02 win (HR 0.42, ASCO 2026-06-01) feeds a rolling NDA under FDA RTOR guided complete H2 2026, and Q2 (2026-08-04) showed ~$1.24B cash with runway into 2030. Nothing company-dated until… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics analysed · ILMN Illumina, Inc. MEDIUM Post-print give-back fully reversed: $187.96 on 2026-08-07 to a 52-week-high close of $219.40 on 2026-08-21 (+51.9% over three months, RSI 66.3) with no new operating news since the 2026-07-30 beat-and-raise. Price now sits above the… Special situation · Medtech & diagnostics · Oncology & immunology analysed · KODK Eastman Kodak Company MEDIUM AM&C inflection is now the entire story: the 2026-08-04 Q2 print put segment revenue at $105M (+40% YoY) and consolidated operational EBITDA at $36M vs $9M, and the ~$9.20 shelf reclaimed on that print has held — the 2026-08-21 close was… Special situation · Cyclical industrials · Industrial power & grid catalyst · NEOG Neogen Corporation MEDIUM Post-3M-integration cleanup is in the numbers after the 2026-07-30 beat-and-raise, but the re-rating has stopped extending: $11.95 close on 2026-08-21, a marginal new high at $12.15, RSI 50.8, no target change since Piper Sandler's $13 on… Special situation · Medtech & diagnostics · M&A & special situations analysed · NKTR Nektar Therapeutics MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… Earnings inflection · Precision biotech & therapeutics · Binary-catalyst biotech catalyst · OXM Oxford Industries, Inc. MEDIUM Setup inverted since the June breakdown. OXM reclaimed its 200-day ($39.11) and 50-day ($39.94) off the $35.83 low, the CEO bought 2,500 shares at $36.90 on 2026-06-12, and ~$25M of filed IEEPA tariff-refund claims — 4% of market cap,… Special situation · Consumer discretionary rotation · M&A & special situations catalyst · PD PagerDuty, Inc. MEDIUM The read has flipped from value trap to ownership story. Price reclaimed the 200-DMA (~$10.30 on 2026-07-17, +13% in three weeks), Truist lifted its PT to $11 on 2026-07-09, and the 2026-07-14 addition of Alex Shootman — who sold Workfront… Special situation · AI enterprise software · M&A & special situations catalyst · PRGS Progress Software Corporation MEDIUM Disciplined software roll-up ("Total Growth Strategy") re-rated by a fresh catalyst cluster: Q2 beat + FY guide raise (2026-06-30) and the $400M Domo buy (2026-07-22). Special-situations theme active, but a maturing low-beta compounder —… Special situation · AI enterprise software · M&A & special situations analysed · PRM Perimeter Solutions, Inc. MEDIUM Monopoly wildfire retardant (PHOS-CHEK) into a season at national Preparedness Level 5 — 3.85M acres burned YTD (NIFC, 7/18), ~157% of the 10-yr average. JPM initiated Overweight $50 on 7/9, lifting the 4-analyst average target to $45.… Defensive · Managed care & health services · M&A & special situations catalyst · RMAX Re/Max Holdings, Inc. fresh MEDIUM Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80… Earnings inflection · M&A & special situations catalyst · ACB Aurora Cannabis Inc. LOW Frame flipped 2026-08-11: Curaleaf's unsolicited proposal — 0.3463 CURLF shares + US$0.75 cash, implied US$4.00, capped at US$5.00 — turned a broken Canadian LP into a live take-over situation. No formal bid has been commenced, the board… Earnings inflection · M&A & special situations · Semi foundry & equipment catalyst · ACHR Archer Aviation Inc. LOW The 2026-08-10 Boeing-subsidiary re-rating has fully retraced: the 2026-08-21 weekly close of $6.30 sits 0.6% above the $6.26 pre-announcement reference, so the market is valuing >$200M of acquired Insitu revenue at roughly nothing. Compounder · Defense & aerospace · Physical AI & robotics analysed · ALOT AstroNova, Inc. LOW Terminal merger-arb pin. Arcline's $29.00 all-cash take-private cleared its HSR condition on 2026-07-31 and goes to a shareholder vote on 2026-08-25; the 2026-08-14 close of $28.91 leaves $0.09 of gross spread against a break tail toward… Earnings inflection · M&A & special situations · Semi foundry & equipment catalyst · ANAB AnaptysBio, Inc. LOW The dateless wait acquired a docket: a 2026-07-28 stipulation set post-trial briefing to an Oct 20 Chancery argument, and ANAB has rebuilt from ~$54 (Jul 24) to $58.47 (Aug 14) on no company news. The written opinion deciding Jemperli… Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · APGE Apogee Therapeutics, Inc. LOW HSR expiry (2026-08-05) and shareholder approval (2026-08-11) cleared the last stated conditions on AbbVie's $135.11 all-cash takeout, so what trades now is terminal merger-arb carry into a company-guided Q3-2026 close — capped at the bid,… Earnings inflection · M&A & special situations · Oncology & immunology analysed · ARX Accelerant Holdings LOW Signed all-cash take-private at $20.25; the 2026-08-21 close of $19.59 leaves a fixed-price insurance-regulatory arb with the ceiling contractually set. Newly visible merger terms — go-shop ending 2026-09-22, outside date 2027-08-13… Earnings inflection · M&A & special situations · Managed care & health services catalyst · ATAI AtaiBeckley Inc. LOW Lilly takeout is now a process, not a story: DEFM14A filed, special meeting 2026-09-08, HSR filed 2026-07-29, close guided Q3 2026. The 2026-08-14 close of $7.26 sits $0.51 over the $6.75 cash leg, so all remaining return is an unread CVR… Earnings inflection · Precision biotech & therapeutics · Semi foundry & equipment catalyst · AVNS Avanos Medical, Inc. LOW Resolved, not pending: AIP completed the $25.00/share all-cash take-private on 2026-07-27 and AVNS ceased NYSE trading the same day (EV ~$1.272B). Holders received cash; there is no listed security, no narrative leg and no catalyst left.… Earnings inflection · M&A & special situations · Medtech & diagnostics analysed · AZTA Azenta, Inc. LOW No new company information since the Aug 4 print, yet price ran from $33.39 (Aug 11) to $37.40 (Aug 21) with RSI(14) at 81.5 and the six-analyst consensus target of $34.80 now below spot. The self-help leg ($529M cash, no debt, $50.0M… Special situation · Medtech & diagnostics · M&A & special situations analysed · BAK Braskem S.A. LOW Q2 2026 (released 2026-08-14) printed US$1.043B recurring EBITDA on a Middle East supply shock management called tactical — and the ADR closed $1.95, pricing the capital structure rather than the P&L. The 2026-06-26 São Paulo shield… Earnings inflection · Biofuels & low-carbon fuels · Emerging markets catalyst · BOLD Boundless Bio, Inc. LOW Merger-arb wrapper, not an oncology stock: the object is a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. Week of 2026-08-14 added owners (ADAR1 13G at 8.8%) but no deal documents — still no S-4,… Earnings inflection · M&A & special situations · Rare disease & gene therapy analysed · BTGO BitGo Holdings, Inc. LOW Broken IPO that cleared its 2026-07-21 lockup without a supply flood but is grinding on the $4.665 all-time low with no bounce; Goldman cut its target to $7.75, and the undated $100M Galaxy verdict plus the ~2026-08-26 Q2 print are the… Earnings inflection · Crypto exchanges & financials · M&A & special situations catalyst · BWMN Bowman Consulting Group Ltd. LOW Not a growth story — a cash-deal spread. Bernhard Capital's $43.00 all-cash take-private (signed 2026-08-10) caps the name; the 2026-08-21 close of $42.61 is $0.39 under it, down from a $0.70 gap on 2026-08-14. The go-shop expires 5:00… Earnings inflection · M&A & special situations · AI datacenter infrastructure catalyst · CBZ CBIZ, Inc. LOW Deal-completion story now, not an operating one: the 2026-08-21 close of $54.66 sits $0.34 under the signed $55.00 all-cash terms, in from $0.54 on 2026-08-14. The go-shop expiring 11:59pm ET 2026-08-27 is the only mechanism that can print… Earnings inflection · M&A & special situations · Semi foundry & equipment catalyst · CCRN Cross Country Healthcare, Inc. LOW Situation settled: the Knox Lane take-private became effective 2026-07-21 at $13.25 cash, Nasdaq suspended trading that morning and filed Form 25 the same day. No listed security, no residual claim, no forward catalyst — any CCRN bar dated… Earnings inflection · M&A & special situations · Managed care & health services analysed · CCXI Churchill Capital Corp XI LOW De-SPAC humanoid pure-play now maturing: Unitree's 2026-08-19 STAR debut (+487% close, ~$53B) lifted CCXI for one session before the move fully round-tripped — $17.07 on 2026-08-14 to $14.57 on 2026-08-21, RSI 73.4 to 43.5. Still no public… Earnings inflection · M&A & special situations · Physical AI & robotics analysed · CMBT CMB.TECH NV LOW July's non-confirmation resolved upward: CMBT closed 2026-08-14 at $17.24, a 52-week high on the adjusted series, RSI 79.4, into a confirmed 2026-08-27 Q2 print whose rates were pre-disclosed on 2026-05-19 (81% of VLCC days at… Special situation · Oil, energy & geopolitical · Freight & logistics catalyst · CNMD CONMED Corporation LOW Six weeks on, the deal leg is still the only unresolved one: no process headline since 2026-07-10, no sell-side action since 2026-07-30, no company event dated inside 30 days — yet price drifted to $51.07 on 2026-08-21, 10.9% above the… Earnings inflection · Medtech & diagnostics · M&A & special situations analysed · CNTA Centessa Pharmaceuticals plc LOW Closed cash-plus-CVR takeout; nothing trades. Lilly's scheme ($38.00 cash plus a non-transferable CVR of up to $9.00) went effective 2026-06-24, Form 15-12G dated 2026-07-06. New since the last note: ClinicalTrials.gov lists a Phase… Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · CPIX Cumberland Pharmaceuticals Inc. LOW Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical… Special situation · M&A & special situations · Precision biotech & therapeutics analysed · CRNX Crinetics Pharmaceuticals, Inc. LOW Not a narrative any more: the Vertex $85.00/share cash takeout cleared HSR on 2026-08-12, the stockholder vote is 2026-08-28, and closing is guided to early September. At the 2026-08-14 close of $84.70 the gap to terms is $0.30 against… Earnings inflection · M&A & special situations · Rare disease & gene therapy catalyst · CRTO Criteo S.A. LOW Takeover-premium leg is dead and the tape kept going: the 2026-07-06 Vista/Quinti gap is fully filled, no party has confirmed anything in 46 days, and the 2026-08-05 guide cut re-based FY26 contribution ex-TAC to $1.034–1.058B from… Earnings inflection · M&A & special situations · AI enterprise software analysed · CXT Crane NXT, Co. LOW Beat-and-raise on 2026-08-05 has been fully sold: the ~$56.23 post-print quote gave way to a $50.20 close on 2026-08-21, RSI 39.3, and 2026-08-19 opened $48.06 with no company release behind it. Organic growth was only 2.8% of the 22%… Special situation · M&A & special situations · Cyclical industrials catalyst · DLTR Dollar Tree Inc. LOW Guide-raise leg resolves in four sessions: the 2026-08-27 Q2 print (8:00 a.m. ET call, Dollar General the same morning) is the binary. At the 2026-08-21 close of $131.48 the stock trades above both aggregated mean targets ($127.32 /… Special situation · Consumer discretionary rotation · M&A & special situations catalyst · DNUT Krispy Kreme, Inc. LOW Attention returned before the fundamentals changed: BofA lifted its target to $4.90 on 2026-08-10 and the Pokémon collection hit shops 2026-08-18, carrying the close from $3.33 (08-14) to $3.59 (08-21) with RSI(14) at 69.9. The… Retail squeeze · Consumer discretionary rotation · M&A & special situations catalyst · EPC Edgewell Personal Care Company LOW Two legs: a refused $30 take-private approach (2026-06-22) and a first clean quarter (fiscal Q3 organic +1.1%, adjusted EPS $0.72 vs $0.62). Sixty days on there is no competing bid, no process and no 13D, and the shares have coiled within… Earnings inflection · M&A & special situations · Consumer discretionary rotation catalyst · ESPR Esperion Therapeutics, Inc. LOW Resolved and off the tape. ARCHIMED's take-private closed 2026-07-13 at $3.16 cash plus a non-tradeable CVR of up to $100M; Nasdaq was asked to file Form 25 the same day and reporting duties are being suspended by Form 15. The early-August… Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · GBTG Global Business Travel Group, Inc. LOW Take-private in its final leg: stockholders adopted the $9.50 Long Lake merger on 2026-08-03, and the 2026-08-14 close of $9.46 leaves $0.04 gross against a roughly 37% break tail to the unaffected $5.93. Only undated offshore regulatory… Earnings inflection · M&A & special situations · Consumer discretionary rotation analysed · GCO Genesco Inc. LOW The operating turnaround is real but priced, and its one asymmetric leg — the activist proxy fight — lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the… Earnings inflection · Consumer discretionary rotation · Cyclical industrials catalyst · HELE Helen of Troy Limited LOW Deleveraging-stub leg broke out: 2026-08-14 close $30.22 is a 52-week closing high with no dated news behind it, above the $26.50 consensus target and both published targets. Forward P/E re-rated 7.55→8.25 on an unchanged $3.25–$3.75 FY27… Special situation · Consumer discretionary rotation · M&A & special situations catalyst · IHRT iHeartMedia, Inc. LOW M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first… Earnings inflection · Cyclical industrials · M&A & special situations analysed · IMRX Immuneering Corporation LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… Earnings inflection · Oncology & immunology · M&A & special situations analysed · IRWD Ironwood Pharmaceuticals, Inc. LOW Post-print drift: the 2026-08-06 binary resolved with FY26 guidance raised (revenue $460–485M, adjusted EBITDA above $310M) but both reported lines missing consensus, and two weeks on the stock is unchanged at $4.29, 20.4% under the $5.39… Earnings inflection · Precision biotech & therapeutics · M&A & special situations analysed · ITGR Integer Holdings Corporation LOW Signed-deal instrument since 2026-08-03: KKR's $127.00 all-cash agreement leaves $1.80 above the 2026-08-21 close of $125.20 (~1.4%), unchanged from two weeks earlier. The paperwork stage has begun with no paperwork — no merger proxy on… Earnings inflection · M&A & special situations · Medtech & diagnostics analysed · JACK Jack In The Box Inc. LOW June's move was a float mechanic — Russell Microcap inclusion (effective 2026-06-30) into a 40%-short float drove $8.92 to $18.13, and it is unwinding ($14.98 on 2026-07-17, -7.76%). SSS is genuinely inflecting (-6.7% → -3.8%), but price… Retail squeeze · Squeeze & momentum setups · Consumer discretionary rotation catalyst · KALV KalVista Pharmaceuticals, Inc. LOW Resolved cash takeout, not a live security: Chiesi's $27.00/share acquisition closed 2026-06-11, KALV delisted the same morning, Form 15-12G filed 2026-06-22, and Rule 12g-4 registration termination lands ~2026-09-20. The 2026-06-10 close… Earnings inflection · M&A & special situations · Rare disease & gene therapy catalyst · KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… Earnings inflection · Oncology & immunology · Precision biotech & therapeutics analysed · LAR Lithium Argentina AG LOW Commodity-beta bounce stopped transmitting: GFEX 2609 extended to CNY 156,140/t on 2026-08-22 while the shares went $6.82 (08-14) to $6.83 (08-21) and RSI cooled 66.8 to 58.6. Lithium-recovery narrative reads saturated; two price targets… Compounder · Critical materials & rare earths · M&A & special situations analysed · LILA Liberty Latin America Ltd. LOW Break-up leg intact but the news flow has flipped from company action to downgrades: Morgan Stanley cut to Underweight $7.00 on 2026-08-20, leaving the 2026-08-21 close of $8.47 above all three dated targets ($6.50/$7.00/$8.00). RSI 51.9… Defensive · M&A & special situations · Emerging markets catalyst · LILAK Liberty Latin America Ltd. LOW Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already… Defensive · M&A & special situations · Emerging markets catalyst · LNC Lincoln National Corp. LOW Legacy-risk-transfer re-rating: the 2026-07-30 Talcott deal cedes ~$5.8B of GUL statutory reserves for ~$200M all-in statutory capital, alongside a Q2 adjusted EPS beat at $2.24 vs $1.96. But the information is out, price sits 2.1% under… Special situation · M&A & special situations · Managed care & health services catalyst · LPRO Open Lending Corporation LOW Terminal, not fading: ANV's $3.15 all-cash tender expired 2026-07-27 with ~85.65% tendered, shares accepted 2026-07-28, §251(h) merger consummated 2026-07-30. Last public close $3.14 on 2026-07-29. As of 2026-08-23 nothing has reopened it… Earnings inflection · Fintech & consumer credit · M&A & special situations analysed · MGM MGM RESORTS INTERNATIONAL LOW Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At… Earnings inflection · M&A & special situations · Prediction markets & betting catalyst · MKTX MarketAxess Holdings, Inc. LOW ICE's $167.00 all-cash agreement (signed 2026-07-30) has fully converted MKTX into a spread instrument, and the spread has drifted wider: $167.00 less the 2026-08-21 close of $162.11 leaves $4.89 gross against an H1 2027 guided close.… Earnings inflection · M&A & special situations · Prediction markets & betting catalyst · OGN Organon & Co. LOW Deal-pinned arb, now purely regulatory: the $14.00 all-cash Sun Pharma offer was approved by holders 2026-07-23 and the 2026-08-21 close of $13.75 leaves $0.25, ~1.8% gross, into a stated early-2027 close. Upside is capped by contract; a… Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · OLPX Olaplex Holdings, Inc. LOW Closed by event and now confirmed from the buyer's side: Henkel's all-cash takeout completed 2026-07-07 at $2.06 per share, Nasdaq delisting and a Form 15-12G followed, and Henkel's 2026-08-06 half-year report carries no brand-level… Earnings inflection · M&A & special situations · Managed care & health services catalyst · OPI Office Properties Income Trust Common shares of beneficial interest LOW First post-reorg print landed 2026-08-05: 77.9% leased, $1.707B debt, the book equity, no dividend. The binary passed without breaking the tape — The narrative has matured from deleveraging re-rate into asset-sale arithmetic with insider… Retail squeeze · M&A & special situations · Housing, homebuilders & proptech analysed · P Everpure, Inc. LOW Hyperscaler design-win re-rating has stalled: 52-week high $118.16 on 2026-08-14, then a 2026-08-21 close of $108.55 with RSI(14) still 79.5 while TD Cowen ($170) and Wedbush ($127) raised targets into the fall. The 2026-08-26 Q2 FY2027… Cyclical recovery · AI datacenter infrastructure · AI chips & memory catalyst · PAYO Payoneer Global Inc. LOW Pure merger-arb, now fully scheduled: HSR early termination granted 2026-07-28 and the 2026-08-11 definitive proxy set the shareholder vote for 2026-09-14, yet the 2026-08-14 close of $7.13 still sits $0.27 under Nuvei's $7.40 all-cash… Earnings inflection · M&A & special situations · Fintech & consumer credit catalyst · PBI Pitney Bowes Inc. LOW PBI broke the $17.62 shelf to a fresh 52-week high $18.62 (Jul 16) — the buyback/cost-cut re-rate is now extending, not consolidating. But revenue still shrinks ~3% YoY, consensus PT $16.43 sits below spot, and Q2 prints after close Jul… Special situation · M&A & special situations · Cyclical industrials catalyst · PII Polaris Inc. LOW The $66 shelf the recovery leg stood on is gone: the 2026-06-05 low of $66.06 broke and PII closed 2026-08-21 at $64.39, three weeks after a beat-and-raise (Q2 sales $2,023M, operational adjusted EPS $1.01 vs a $0.70–0.80 guide). The… Special situation · Cyclical industrials · Consumer discretionary rotation analysed · PLTK Playtika Holding Corp. LOW The control-premium bid is gone and the markdown extended: the 2026-08-21 weekly close of $2.37 took out the $2.51 shelf, RSI(14) 12.9, 44.4% under the $4.26 52-week high. The one new disclosure is financing rather than a sale — 2026-08-18… Earnings inflection · M&A & special situations · Consumer discretionary rotation analysed · RAMP LiveRamp Holdings, Inc. LOW Shareholder gate cleared 2026-08-17: 51,578,202 shares voted to adopt versus 60,073 against, leaving CFIUS, HSR and non-US clearances as the only unconfirmed conditions on Publicis' $38.50 cash offer. The 2026-08-21 close of $37.58 sits… Earnings inflection · M&A & special situations · AI enterprise software analysed · REAX The Real Brokerage, Inc. fresh LOW Hypergrowth brokerage story has decelerated (Q1 rev +32% vs 70%+ historically, a forecast miss) and the stock sits near 52-week lows after the $880M RE/MAX deal spooked investors on dilution. The read is now a binary consolidation bet, not… Earnings inflection · M&A & special situations catalyst · RFAI RF Acquisition Corp II fresh LOW Near-total redemption — 3,956,323 of 3,998,108 public shares, 98.95% — left almost no tradable float into the 2026-08-19 Nanyang Biologics approval, and RFAI ran +524.3% on the week to close $58.00. The leg being bought is a mechanical… Retail squeeze · M&A & special situations analysed · RLYB Rallybio Corporation LOW No new filing since the 2026-08-06 10-Q: as of 2026-08-23 the 2026-07-15 S-4 is still not effective, with no record date or meeting date set. The 2026-08-21 close of $16.83 sits ~7% above the ~$15.68/share implied by the S-4's $83.2M Net… Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · RPAY Repay Holdings Corporation LOW The bid discount narrowed on an operating headline: the close ran $3.66 (2026-08-14) to $4.01 (2026-08-21) after REPAY joined Visa Platform Connect on 2026-08-19, leaving Forager's rejected $5.25 cash proposal ~31% above the tape with no… Earnings inflection · M&A & special situations · Fintech & consumer credit analysed · SEER Seer, Inc. LOW The take-private ladder has stalled into a stand-off: the $2.55 Radoff-JEC bid lapsed unanswered on 2026-08-10, and the group's 2026-08-13 release demanding the board disclose an evaluation timeline has drawn no company reply through the… Earnings inflection · M&A & special situations · Medtech & diagnostics analysed · SITM SiTime Corporation LOW MEMS-timing picks-and-shovels story is fundamentally intact — Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 — but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close… Cyclical recovery · AI datacenter infrastructure · Networking & optical analysed · SMTI Sanara MedTech Inc. LOW Merger-arb instrument since MIMEDX's 2026-07-29 agreement ($33.00 cash + 0.4735 MDXG per share). The 2026-08-11 Form 425 disclosed a 2027-07-29 outside date, a $22.5M reverse termination fee and 38.9% voting lock-up; at the $34.45 close… Earnings inflection · Medtech & diagnostics · M&A & special situations analysed · STAA STAAR Surgical Company LOW Structure broken, no dated catalyst before the ~2026-10-07 pre-release window. Earnings inflection · Medtech & diagnostics · Semi foundry & equipment analysed · SYNA Synaptics Incorporated LOW Standalone story ended at the 2026-06-25 all-stock takeout; The week to 2026-08-21 proved it — ON -10.2%, SYNA -10.1%, discount still ~2.5% (1.350 x $74.21 = $100.18 vs $97.66). The S-4 filed 2026-08-21 puts the vote on the clock and… Earnings inflection · M&A & special situations · Analog semiconductors catalyst · TBRG TruBridge, Inc. LOW Closed and now formally deregistered: the IKS Health merger became effective 2026-07-09 at $26.25/share cash, Form 25 filed the same day, Form 15-12G on 2026-07-24. The adjusted series ends 2026-07-08 at $26.24. A screen still surfacing… Earnings inflection · M&A & special situations · Managed care & health services analysed · TECH Bio-Techne Corp LOW Closed merger-arb pinned $0.60 under Merck KGaA's $73.00 all-cash bid — 2026-08-14 close $72.40, also the 52-week high. Q4 printed 08-12 with no call and no FY27 guidance; Wells Fargo folded to a $73 target on 08-13. Coverage is fully… Earnings inflection · Medtech & diagnostics · Precision biotech & therapeutics analysed · TIC TIC Solutions, Inc LOW Post-merger re-rate: engineering/geospatial backlog hit a record $1.18B (+20% YoY) on 2026-08-06 while legacy inspection fell ~5.5% combined, and UBS's 2026-08-11 upgrade (Buy, PT $12.50 from $11.00) prices an inflection that Q2's +2.5%… Special situation · M&A & special situations analysed · TORO Toro Corp. LOW Panagiotidis shipping shell (NOT lawnmower TTC) ran 1.93→8.50 on a sub-NAV/special-dividend story that is now fully paid out and closed. Six weeks of dead tape since the 2026-06-05 payout ($3.8M cash + 5,707,246 NEW shares); on a true… Retail squeeze · Freight & logistics · M&A & special situations catalyst · TRIP TripAdvisor, Inc. LOW Activist sum-of-the-parts leg broke: Q2 revenue $441.9M missed consensus $503.9M on 2026-08-06 (~-20% day), four targets cut to $9–$12.50 by 08-11, and the $11–13 base gave way to a $10.74 close on 2026-08-14 with RSI 25. What's left is an… Special situation · M&A & special situations · Travel & leisure analysed · UNIT Uniti Group Inc. LOW Hyperscaler dark-fiber demand turned the post-Windstream deleveraging grind into a growth story (~$1.5B disclosed funnel, $68.7M of Q1 IRU revenue from one hyperscaler), but the June re-rate to ~$11 has stalled in a three-week range above… Special situation · AI datacenter infrastructure · Biofuels & low-carbon fuels analysed · VECO Veeco Instruments Inc. LOW Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes cleared 2026-02-06, only China SAMR remains before the 2026-09-30 outside date. ACLS's slide to ~$134 de-pegged VECO to a premium over the exchange ratio (~$48) —… Earnings inflection · M&A & special situations · Semi foundry & equipment analysed · WLFC Willis Lease Finance Corporation LOW Engine-leasing supercycle still printing records (Q1 rev +23%, EPS $4.03 vs $3.02 est), but the theme is maturing and the stock has faded ~18% off its 2026-07-06 ATH into the now-completed 3-for-1 split. The event stack has collapsed to… Cyclical recovery · Space economy · Small-cap value rotation catalyst · WSC WillScot Holdings Corporation LOW Cyclical modular-space leasing recovery with a small data-center kicker and an activist/M&A floor, but range-bound and digesting: shares drifted to ~$26 under the $31.88 high after the 2026-06-27 Russell growth-index removal. The confirmed… Theme leader · AI datacenter infrastructure · Industrial power & grid analysed · XHG XChange TEC.INC LOW Sub-$1 China insurance ADS re-rated ~4x in two sessions on a 2026-08-13 non-binding LOI to acquire HK AI insurtech First Cycle — terms undisclosed, subject to definitive agreements. The leg being bought is an AI-insurance pivot; the FY2025… Retail squeeze · M&A & special situations analysed · XRX Xerox Holdings Corporation LOW Distressed-deleveraging special situation that round-tripped its June activist pop into a binary 2026-07-30 Q2 print. At ~$2.60 it sits below the $2.75 Hold consensus and inside the $2.25–$2.50 target band; anchor buyer STARTEEPO (8.8M sh,… Special situation · M&A & special situations · Cyclical industrials analysed · XTLB XTL Biopharmaceuticals Ltd. LOW Delisting binary fully resolved — Nasdaq confirmed compliance 2026-07-20 — and the pivot pop has bled off: no dated company release since, ADS $2.94 (2026-07-25) → $2.79 (2026-08-14), RSI 44.4. Event narrative is saturated; the next leg… Special situation · Precision biotech & therapeutics · M&A & special situations analysed ·